Pulmonary Surfactant Therapy Improves Outcomes in Neonatal Respiratory Distress Syndrome: Study

China: Researchers have found in a new study that pulmonary surfactant (PS) therapy significantly improves arterial blood gas parameters and clinical symptoms in infants with neonatal respiratory distress syndrome (NRDS), demonstrating good safety. Additionally, lung ultrasound (LUS) scoring helps guide treatment decisions and offers predictive value for therapeutic response, providing a practical tool for effective clinical management of NRDS.
- Pulmonary surfactant therapy led to significant improvements in infants with neonatal respiratory distress syndrome (NRDS).
- After treatment, the partial pressure of carbon dioxide, chest X-ray severity grading, lung ultrasound scores, and visible respiratory distress signs decreased significantly.
- At the same time, the partial pressure of oxygen and blood pH levels increased significantly.
- The overall clinical improvement rate following therapy was 90.91%, indicating strong treatment effectiveness.
- Lung ultrasound scores showed a positive correlation with chest X-ray grading both before and after treatment, suggesting that LUS accurately reflects the severity of lung involvement in NRDS.
- Early chest X-ray grading and bilateral LUS scores were able to predict clinical improvement after surfactant therapy.
- Lung ultrasound demonstrated stronger predictive performance for treatment response compared with chest X-ray.
- The therapy was generally well tolerated, with adverse reactions reported in 8.08% of treated infants, indicating an acceptable safety profile.
Apa Reaksi Anda?
Suka
0
Kurang Suka
0
Setuju
0
Tidak Setuju
0
Bagus
0
Berguna
0
Hebat
0
